EP1009236A4 - Evaluierung, verabreichung und verwendung von mitteln zur behandlung vonherzerkrankungen - Google Patents

Evaluierung, verabreichung und verwendung von mitteln zur behandlung vonherzerkrankungen

Info

Publication number
EP1009236A4
EP1009236A4 EP98934656A EP98934656A EP1009236A4 EP 1009236 A4 EP1009236 A4 EP 1009236A4 EP 98934656 A EP98934656 A EP 98934656A EP 98934656 A EP98934656 A EP 98934656A EP 1009236 A4 EP1009236 A4 EP 1009236A4
Authority
EP
European Patent Office
Prior art keywords
evaluation
delivery
agents
treat heart
heart disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98934656A
Other languages
English (en)
French (fr)
Other versions
EP1009236A1 (de
Inventor
Roger J Hajjar
Anthony Rosenzweig
Luis Guerrero
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Priority to EP03012035A priority Critical patent/EP1374909A3/de
Publication of EP1009236A1 publication Critical patent/EP1009236A1/de
Publication of EP1009236A4 publication Critical patent/EP1009236A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP98934656A 1997-07-22 1998-07-20 Evaluierung, verabreichung und verwendung von mitteln zur behandlung vonherzerkrankungen Withdrawn EP1009236A4 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP03012035A EP1374909A3 (de) 1997-07-22 1998-07-20 Evaluierung, Verabreichung und Verwendung von Mitteln zur Behandlung von Herzerkrankungen

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5335697P 1997-07-22 1997-07-22
US53356P 1997-07-22
PCT/US1998/014968 WO1999004636A1 (en) 1997-07-22 1998-07-20 Evaluation of, delivery of, and use of agents to treat heart disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP03012035A Division EP1374909A3 (de) 1997-07-22 1998-07-20 Evaluierung, Verabreichung und Verwendung von Mitteln zur Behandlung von Herzerkrankungen

Publications (2)

Publication Number Publication Date
EP1009236A1 EP1009236A1 (de) 2000-06-21
EP1009236A4 true EP1009236A4 (de) 2000-10-25

Family

ID=21983650

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98934656A Withdrawn EP1009236A4 (de) 1997-07-22 1998-07-20 Evaluierung, verabreichung und verwendung von mitteln zur behandlung vonherzerkrankungen

Country Status (3)

Country Link
EP (1) EP1009236A4 (de)
CA (1) CA2297328A1 (de)
WO (1) WO1999004636A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1171628A2 (de) * 1999-04-15 2002-01-16 Devgen NV Verfahren zum screening von verbindungen
DE10126371A1 (de) * 2001-05-30 2003-02-27 Medigene Ag Verfahren zur Identifizierung von Substanzen gegen Herzmuskelzellen-Hypertrophie
WO2005023292A1 (en) 2003-09-03 2005-03-17 The General Hospital Corporation Methods of treating restenosis

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HAJJAR, ROGER J. ET AL: "Modulation of ventricular function through gene transfer in vivo", PROC. NATL. ACAD. SCI. U. S. A. (1998), 95(9), 5251-5256, XP002141696 *
HOIT, B.D. ET AL.: "Influence of transgenic overexpression of phospholamban on postextrasystolic potentation", JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, vol. 31, no. 11, November 1999 (1999-11-01), pages 2007 - 2015, XP002141698 *
NEUMANN, J. ET AL.: "Targeted overexpression of phospholamban to mouse atrium depresses Ca2+ transport and contractility", JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, vol. 30, no. 10, October 1998 (1998-10-01), pages 1991 - 2002, XP002141697 *
See also references of WO9904636A1 *

Also Published As

Publication number Publication date
WO1999004636A1 (en) 1999-02-04
EP1009236A1 (de) 2000-06-21
WO1999004636A9 (en) 1999-04-29
CA2297328A1 (en) 1999-02-04

Similar Documents

Publication Publication Date Title
HUP0100069A3 (en) 4(3)substituted-4(3)-aminomethyl-pyran, or -thiopyran-piperidine derivatives, their preparation and their use in the treatment of neurological disorders
HUP0004439A3 (en) 1-substituted-1-aminomethyl-cycloalkane derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders
HRP20000201B1 (en) Prostaglandin agonists and their use to treat bone disorders
EP0959908A4 (de) Neue zielgerichtete kontrastmittel für diagnostische und therapeutische verwendungen
HUP0100786A3 (en) Substituted 2-phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them
AU6530600A (en) Use of neurotoxin for treating cardiac muscle disorders
PL339425A1 (en) Treatment of behavioural disorders
HUP0000496A3 (en) Heterocyclically substituted benzamides and their use in fighting diseases
HUP0002030A3 (en) Use of glur5 receptorantagonists for the treatment of pain
EP0892632A4 (de) Mittel zur verwendung in der phototherapeutischen behandlung proliferativer hautstörungen
NZ330360A (en) 5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents
IL129144A0 (en) Use of 1-hydroxy-2-pyridones for the treatment of skin diseases
EP1126850A4 (de) Behandlung von retinalerkrankungen
HUP0101528A3 (en) The treatment of fertility disorders use of lhrh antagonists and antioestrogens in
PL336760A1 (en) Treatment of skin diseases
HK1112738A1 (en) Arylsulfonamides and analogues as well as use for the treatment of neuro- degenerative disorders
PL345110A1 (en) Aza-heterocyclic compounds used to treat neurological disorders and hair loss
EP0915826A4 (de) Spasmolytische mittel für die glatte muskulatur und verfahren zu ihrer anwendung
ID23175A (id) Penggunaan benzopiranol untuk mengobati gangguan syaraf
EP1009236A4 (de) Evaluierung, verabreichung und verwendung von mitteln zur behandlung vonherzerkrankungen
IL131347A0 (en) Treatment of skin disorders
IL129460A0 (en) Use of lofexidine in the treatment of behavioral disorders
GB9419048D0 (en) Treatment of muscular disorders
AU8799398A (en) Physiological combination of active substances to enhance the skin's defenses against noxious agents
ZA978921B (en) Therapeutic use of hemoglobin to treat head injury.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000221

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): CH DE ES FR GB LI

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 01N 63/00 A, 7A 01N 43/04 B, 7C 12Q 1/68 B, 7C 12N 15/64 B, 7C 12N 5/00 B, 7C 07H 21/04 B, 7G 01N 33/50 B

A4 Supplementary search report drawn up and despatched

Effective date: 20000907

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): CH DE ES FR GB LI

17Q First examination report despatched

Effective date: 20011119

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050826